Meiji Yasuda Asset Management Co Ltd. Has $1.40 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Meiji Yasuda Asset Management Co Ltd. lifted its holdings in Kenvue Inc. (NYSE:KVUE) by 3.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 65,376 shares of the company’s stock after purchasing an additional 2,041 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Kenvue were worth $1,396,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Grove Bank & Trust lifted its position in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue in the fourth quarter valued at about $29,000. SRS Capital Advisors Inc. raised its holdings in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after acquiring an additional 571 shares in the last quarter. Fortitude Family Office LLC boosted its position in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc grew its stake in Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Barclays dropped their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and cut their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Citigroup dropped their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Canaccord Genuity Group lifted their price target on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, Evercore ISI began coverage on Kenvue in a research note on Monday. They issued an “in-line” rating and a $25.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $23.85.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $23.40 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a market cap of $44.72 billion, a price-to-earnings ratio of 44.15, a P/E/G ratio of 2.62 and a beta of 1.25. The stock’s fifty day moving average price is $22.22 and its two-hundred day moving average price is $22.45. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. Kenvue’s payout ratio is 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.